Target Information

Target General Information

Target ID

T40474 (Former ID: TTDC00110)

Target Name

Proto-oncogene c-Met (MET)

Synonyms

Tyrosine-protein kinase Met; Scatter factor receptor; SF receptor; Met proto-oncogene tyrosine kinase; Hepatocyte growth factor receptor; HGF/SF receptor; HGF-SF receptor; HGF receptor; C-met; C-Met receptor tyrosine kinase

Gene Name

MET

Target Type

Successful target

[1]

Disease

[+] 3 Target-related Diseases

Lung cancer [ICD-11: 2C25]

Non-small cell lung cancer [ICD-11: 2C25]

Thyroid cancer [ICD-11: 2D10]

Function

Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling plays a role in gastrulation, development and migration of muscles and neuronal precursors, angiogenesis and kidney formation. In adults, participates in wound healing as well as organ regeneration and tissue remodeling. Promotes also differentiation and proliferation of hematopoietic cells. May regulate cortical bone osteogenesis. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand.

Click to Show/Hide

BioChemical Class

Kinase

UniProt ID

MET_HUMAN

EC Number

EC 2.7.10.1

Sequence

MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEH
HIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMAL
VVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSAL
GAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPE
FRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECIL
TEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRS
AMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEF
TTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFL
LDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGW
CHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKK
TRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYSTFSYVDPVIT
SISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILECYTPAQTISTEF
AVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVH
EAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPV
FKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDL
LKLNSELNIEWKQAISSTVLGKVIVQPDQNFTGLIAGVVSISTALLLLLGFFLWLKKRKQ
IKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGS
CRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHF
NEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVL
SLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKF
VHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKF
TTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCW
HPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDNADDEVD
TRPASFWETS

Click to Show/Hide

3D Structure

Click to Show 3D Structure of This Target

AlphaFold

HIT2.0 ID

T92AMR

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 4 Approved Drugs

Cabozantinib

Drug Info

Approved

Thyroid cancer

[2], [3]

Capmatinib

Drug Info

Approved

Non-small-cell lung cancer

[4]

Crizotinib

Drug Info

Approved

Non-small-cell lung cancer

[5], [6]

Tepotinib

Drug Info

Approved

Non-small cell lung cancer

[7]

Clinical Trial Drug(s)

[+] 41 Clinical Trial Drugs

Amivantamab

Drug Info

Phase 3

Non-small-cell lung cancer

[8]

Beperminogene perplasmid

Drug Info

Phase 3

Heart disease

[9]

RG3638

Drug Info

Phase 3

Non-small-cell lung cancer

[10]

Savolitinib

Drug Info

Phase 3

Renal cell carcinoma

[11]

Tivantinib

Drug Info

Phase 3

Solid tumour/cancer

[12], [13]

MGCD516

Drug Info

Phase 2/3

Solid tumour/cancer

[14]

AMG 208

Drug Info

Phase 2

Solid tumour/cancer

[15]

AMG 337

Drug Info

Phase 2

Solid tumour/cancer

[16]

APL-101

Drug Info

Phase 2

Non-small cell lung cancer

[17]

CMX-2043

Drug Info

Phase 2

Myocardial reperfusion injury

[18]

Emibetuzumab

Drug Info

Phase 2

Solid tumour/cancer

[19]

HM-5016504

Drug Info

Phase 2

Solid tumour/cancer

[20]

LY-2875358

Drug Info

Phase 2

Solid tumour/cancer

[21]

LY2801653

Drug Info

Phase 2

Solid tumour/cancer

[22]

SAR-125844

Drug Info

Phase 2

Solid tumour/cancer

[23]

Telisotuzumab vedotin

Drug Info

Phase 2

Non-small-cell lung cancer

[24]

XL880

Drug Info

Phase 2

Squamous head and neck cell carcinom

[25], [26]

Anti-C-met CAR-T cells

Drug Info

Phase 1/2

Colorectal cancer

[27]

ChronSeal

Drug Info

Phase 1/2

Fibrosis

[28]

MK-2461

Drug Info

Phase 1/2

Alzheimer disease

[29]

Sym015

Drug Info

Phase 1/2

Solid tumour/cancer

[11], [19]

ABBV-399

Drug Info

Phase 1

Solid tumour/cancer

[30]

ABT-700

Drug Info

Phase 1

Advanced solid tumour

[31]

Altiratinib

Drug Info

Phase 1

Solid tumour/cancer

[32]

Autologous T Cells Expressing MET scFv CAR

Drug Info

Phase 1

Melanoma

[33]

BPI-9016 M

Drug Info

Phase 1

Solid tumour/cancer

[34]

C-Met/PD-L1 CAR-T Cell

Drug Info

Phase 1

Hepatocellular carcinoma

[35]

CBT-101

Drug Info

Phase 1

Solid tumour/cancer

[11]

E-7050

Drug Info

Phase 1

Head and neck cancer

[36], [37]

EMD-1204831

Drug Info

Phase 1

Solid tumour/cancer

[38]

Hepapoietin

Drug Info

Phase 1

Liver disease

[39]

JNJ-38877605

Drug Info

Phase 1

Solid tumour/cancer

[40]

LY3164530

Drug Info

Phase 1

Advanced cancer

[41]

MK-8033

Drug Info

Phase 1

Solid tumour/cancer

[42]

PF-4217903

Drug Info

Phase 1

Solid tumour/cancer

[43]

REGN5093

Drug Info

Phase 1

Non-small-cell lung cancer

[44]

RXDX-106

Drug Info

Phase 1

Solid tumour/cancer

[45]

SGX523

Drug Info

Phase 1

Solid tumour/cancer

[46], [47]

TPX-0022

Drug Info

Phase 1

Solid tumour/cancer

[48]

TR1801-ADC

Drug Info

Phase 1

Solid tumour/cancer

[49]

XL092

Drug Info

Phase 1

Solid tumour/cancer

[50]

Preclinical Drug(s)

[+] 2 Preclinical Drugs

Mteron-F1

Drug Info

Preclinical

Mucositis

[51]

NPS-1034

Drug Info

Preclinical

Solid tumour/cancer

[52]

Mode of Action

[+] 5 Modes of Action

Inhibitor

[+] 49 Inhibitor drugs

Cabozantinib

Drug Info

[3], [53]

Amivantamab

Drug Info

[54]

Savolitinib

Drug Info

[11]

Tivantinib

Drug Info

[12]

MGCD516

Drug Info

[56]

MGCD516

Drug Info

[57]

APL-101

Drug Info

[60]

Emibetuzumab

Drug Info

[19]

HM-5016504

Drug Info

[56]

SAR-125844

Drug Info

[66]

BMS-777607

Drug Info

[69]

ChronSeal

Drug Info

[70]

MK-2461

Drug Info

[29]

Sym015

Drug Info

[11]

ABBV-399

Drug Info

[19]

Altiratinib

Drug Info

[53], [72]

BPI-9016 M

Drug Info

[73]

CBT-101

Drug Info

[11]

EMD-1204831

Drug Info

[75]

Hepapoietin

Drug Info

[76]

JNJ-38877605

Drug Info

[77]

MK-8033

Drug Info

[79]

PF-4217903

Drug Info

[80]

REGN5093

Drug Info

[81]

RXDX-106

Drug Info

[82]

SGX523

Drug Info

[83]

TPX-0022

Drug Info

[84]

XL092

Drug Info

[86]

NPS-1034

Drug Info

[87]

1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine

Drug Info

[88]

1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine

Drug Info

[88]

1-benzyl-1H-pyrrolo[3,2-b]pyridine

Drug Info

[88]

3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine

Drug Info

[88]

AM7

Drug Info

[89]

Anti-cMET mab

Drug Info

[56]

APS-3010

Drug Info

[56]

BAY-85-3474

Drug Info

[56]

BMS-536924

Drug Info

[90]

CMET Avimer polypeptides

Drug Info

[56]

DP-3590

Drug Info

[56]

PF-00614435

Drug Info

[56]

PHA-665752

Drug Info

[56]

PMID21123062C27

Drug Info

[92]

PMID21967808CR-16

Drug Info

[93]

PMID24210504C1o

Drug Info

[94]

PRS-110

Drug Info

[56]

RP-1040

Drug Info

[56]

SU11274

Drug Info

[95]

TP-801

Drug Info

[56]

Modulator

[+] 14 Modulator drugs

Capmatinib

Drug Info

[4]

Crizotinib

Drug Info

[1]

Tepotinib

Drug Info

[7]

Beperminogene perplasmid

Drug Info

[55]

RG3638

Drug Info

[56]

AMG 208

Drug Info

[58]

AMG 337

Drug Info

[59]

CMX-2043

Drug Info

[61]

LY2801653

Drug Info

[64], [65]

XL880

Drug Info

[68]

ABT-700

Drug Info

[71]

E-7050

Drug Info

[74]

LY3164530

Drug Info

[78]

GE-137

Drug Info

[91]

CAR-T-Cell-Therapy

[+] 2 CAR-T-Cell-Therapy drugs

Anti-C-met CAR-T cells

Drug Info

[27]

Autologous T Cells Expressing MET scFv CAR

Drug Info

[33]

CAR-T-Cell-Therapy(Dual specific)

[+] 1 CAR-T-Cell-Therapy(Dual specific) drugs

C-Met/PD-L1 CAR-T Cell

Drug Info

[35]

Stimulator

[+] 1 Stimulator drugs

Mteron-F1

Drug Info

[51]

Chemical Structure based Activity Landscape of Target

Top

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

Co-Targets

Top

Co-Targets

Co-Targets Info

Target Poor or Non Binders

Top

Target Poor or Non Binders

Target Poor or Non Binders Info

Target Regulators

Top

Target-regulating microRNAs

Target-regulating microRNAs Info

Target-interacting Proteins

Target-interacting Proteins Info

Target Profiles in Patients

Top

Target Expression
Profile (TEP)

Target Expression Profile Info

Target Affiliated Biological Pathways		Top
KEGG Pathway	[+] 18 KEGG Pathways	+
1	Ras signaling pathway
2	Rap1 signaling pathway
3	Cytokine-cytokine receptor interaction
4	Endocytosis
5	PI3K-Akt signaling pathway
6	Axon guidance
7	Focal adhesion
8	Adherens junction
9	Bacterial invasion of epithelial cells
10	Epithelial cell signaling in Helicobacter pylori infection
11	Malaria
12	Pathways in cancer
13	Transcriptional misregulation in cancer
14	Proteoglycans in cancer
15	MicroRNAs in cancer
16	Renal cell carcinoma
17	Melanoma
18	Central carbon metabolism in cancer
PID Pathway	[+] 10 PID Pathways	+
1	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
2	Arf6 signaling events
3	Signaling events mediated by TCPTP
4	Posttranslational regulation of adherens junction stability and dissassembly
5	Direct p53 effectors
6	Syndecan-1-mediated signaling events
7	Stabilization and expansion of the E-cadherin adherens junction
8	a6b1 and a6b4 Integrin signaling
9	FGF signaling pathway
10	Regulation of retinoblastoma protein
Reactome	[+] 1 Reactome Pathways	+
1	Sema4D mediated inhibition of cell attachment and migration
WikiPathways	[+] 10 WikiPathways	+
1	TGF beta Signaling Pathway
2	Signaling of Hepatocyte Growth Factor Receptor
3	Focal Adhesion
4	Extracellular vesicle-mediated signaling in recipient cells
5	Signaling Pathways in Glioblastoma
6	miR-targeted genes in squamous cell - TarBase
7	miR-targeted genes in muscle cell - TarBase
8	miR-targeted genes in lymphocytes - TarBase
9	miR-targeted genes in epithelium - TarBase
10	Semaphorin interactions

Target-Related Models and Studies

Top

Target Validation

Target Validation Info

References

Top

REF 1

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 2

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5887).

REF 3

Clinical pipeline report, company report or official report of Exelixis (2011).

REF 4

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020

REF 5

REF 6

2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.

REF 7

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021

REF 8

ClinicalTrials.gov (NCT04538664) A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON). U.S. National Institutes of Health.

REF 9

ClinicalTrials.gov (NCT02144610) Safety and Efficacy of Subjects With Critical Limb Ischemia. U.S. National Institutes of Health.

REF 10

ClinicalTrials.gov (NCT02488330) An Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study.

REF 11

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 12

REF 13

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs. 2014 Apr;32(2):355-61.

REF 14

ClinicalTrials.gov (NCT04887870) Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study. U.S. National Institutes of Health.

REF 15

ClinicalTrials.gov (NCT02420587) AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC). U.S. National Institutes of Health.

REF 16

ClinicalTrials.gov (NCT02016534) Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors. U.S. National Institutes of Health.

REF 17

ClinicalTrials.gov (NCT04258033) A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation. U.S. National Institutes of Health.

REF 18

ClinicalTrials.gov (NCT02103959) Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography. U.S. National Institutes of Health.

REF 19

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 20

ClinicalTrials.gov (NCT02127710) A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC). U.S. National Institutes of Health.

REF 21

ClinicalTrials.gov (NCT01900652) A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants. U.S. National Institutes of Health.

REF 22

ClinicalTrials.gov (NCT01285037) A Study of LY2801653 in Advanced Cancer. U.S. National Institutes of Health.

REF 23

ClinicalTrials.gov (NCT02435121) A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification. U.S. National Institutes of Health.

REF 24

ClinicalTrials.gov (NCT03539536) Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer. U.S. National Institutes of Health.

REF 25

REF 26

Clinical pipeline report, company report or official report of Exelixis (2011).

REF 27

ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

REF 28

ClinicalTrials.gov (NCT00797706) Phase I/II Dose Ranging CHRONSEAL Study in Venous Leg Ulcers. U.S. National Institutes of Health.

REF 29

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.

REF 30

ClinicalTrials.gov (NCT02099058) A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors. U.S. National Institutes of Health.

REF 31

ClinicalTrials.gov (NCT01472016) Study of ABT-700 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.

REF 32

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040094)

REF 33

ClinicalTrials.gov (NCT03060356) Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)

REF 34

ClinicalTrials.gov (NCT02478866) Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.

REF 35

ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC

REF 36

REF 37

ClinicalTrials.gov (NCT02533102) Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers.

REF 38

ClinicalTrials.gov (NCT01110083) First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health.

REF 39

Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Aliment Pharmacol Ther. 2002 Feb;16(2):235-42.

REF 40

ClinicalTrials.gov (NCT00651365) A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.. U.S. National Institutes of Health.

REF 41

ClinicalTrials.gov (NCT02221882) A Study of LY3164530 in Participants With Cancer

REF 42

ClinicalTrials.gov (NCT00559182) A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001). U.S. National Institutes of Health.

REF 43

ClinicalTrials.gov (NCT00706355) A Study of PF-04217903 in Patients With Advanced Cancer. U.S. National Institutes of Health.

REF 44

ClinicalTrials.gov (NCT04077099) REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer. U.S. National Institutes of Health.

REF 45

ClinicalTrials.gov (NCT03454243) Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors (TITAN). U.S. National Institutes of Health.

REF 46

REF 47

ClinicalTrials.gov (NCT00607399) Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors. U.S. National Institutes of Health.

REF 48

ClinicalTrials.gov (NCT03993873) Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET. U.S. National Institutes of Health.

REF 49

ClinicalTrials.gov (NCT03859752) TR1801-ADC in Patients With Tumors That Express c-Met. U.S. National Institutes of Health.

REF 50

ClinicalTrials.gov (NCT03845166) A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors. U.S. National Institutes of Health.

REF 51

Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.

REF 52

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153.

REF 53

Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751.

REF 54

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.

REF 55

Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.

REF 56

REF 57

Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res. 2011 May 1;17(9):2638-45.

REF 58

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30;6(21):18693-706.

REF 59

J Clin Oncol 32:5s, 2014 (suppl; abstr 2508).

REF 60

Clinical pipeline report, company report or official report of Apollomics.

REF 61

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 62

Clinical pipeline report, company report or official report of Eli Lilly.

REF 63

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70.

REF 64

Clinical pipeline report, company report or official report of Eli Lilly.

REF 65

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs. 2013 Aug;31(4):833-44.

REF 66

The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 2015 Feb;14(2):384-94.

REF 67

Clinical pipeline report, company report or official report of AbbVie.

REF 68

Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

REF 69

Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607... J Med Chem. 2009 Mar 12;52(5):1251-4.

REF 70

Clinical pipeline report, company report or official report of Kringle Pharma.

REF 71

J Clin Oncol 32:5s, 2014 (suppl; abstr 2507).

REF 72

Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.

REF 73

First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6.

REF 74

E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5.

REF 75

2012 ASCO Annual Meeting.

REF 76

Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Alimentary Pharmacology & Therapeutics Volume 16, Issue 2, pages 235-242, February 2002.

REF 77

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 2015 May 15;21(10):2297-304.

REF 78

Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.

REF 79

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.

REF 80

Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47.

REF 81

Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.

REF 82

National Cancer Institute Drug Dictionary (drug name RXDX106).

REF 83

CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.

REF 84

Clinical pipeline report, company report or official report of Turning Point Therapeutics.

REF 85

TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68.

REF 86

Clinical pipeline report, company report or official report of Exelixis.

REF 87

NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants. Invest New Drugs. 2014 Jun;32(3):389-99.

REF 88

Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4.

REF 89

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 2008 Feb 1;283(5):2675-83.

REF 90

Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.

REF 91

Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 2015 Aug;21(8):955-61.

REF 92

Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):164-7.

REF 93

Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84.

REF 94

Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6.

REF 95

Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther. 2003 Nov;2(11):1085-92.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Yuzong CHEN

Prof. Feng ZHU